Doris Pharmaceuticals

The principal of Doris Pharmaceuticals is Douglas Berger, M.D., Ph.D.

Dr. Berger has many years of pharmaceutical experience in Japan in positions including Director of Clinical Development and Project Manager for Clinical Development, and has served for a number of years on the R&D Portfolio Review Board of a for a multinational pharmaceutical corporation's Japan office.

Dr. Doug Berger has extensive clinical development project management experience in Japan over a wide-range of products including the design and planning of bridging studies, interaction with the arms of the regulatory agency: the MHLW (Japanese Ministry of Health, Labor, and Welfare), and the PMDA. and licensing negotiations.

Dr. Berger graduated Magna Cum Laude from the University of Connecticut with an undergraduate double major in biology and pathobiology, and a minor in anthropology. He then obtained his M.D. from New York Medical College with Alpha Omega Alpha honors, completed a 4-year residency program in psychiatry at the New York Medical College Department of Psychiatry, and is an American Board-Certified Psychiatrist.

Now based in Tokyo, Dr. Berger had been on the Faculty of the Albert Einstein College of Medicine Department of Psychiatry in New York as an Assistant Professor of Psychiatry. He has done research at a number of Japanese Universities and has a Ph.D. in Neuropsychiatry from the University of Tokyo School of Medicine. Dr. Berger has also completed an intensive MBA preview course at the General Business and Management Division of Temple University Japan. For more information on Dr. Doug Berger, please see the following page.

Publications by Dr. Douglas Berger, psychiatrist in Tokyo:

Berger D: DOUBLE-BLINDING AND BIAS IN MEDICATION AND COGNITIVE-BEHAVIORAL THERAPY TRIALS FOR MAJOR DEPRESSIVE DISORDER, F1000Research 2016, 4:638 (doi: 10.12688/f1000research.6953.2). U.S. National Library of Medicine version.

Berger D: DOUBLE BLINDING REQUIREMENT FOR VALIDITY CLAIMS IN COGNITIVE-BEHAVIORAL THERAPY INTERVENTION TRIALS FOR MAJOR DEPRESSIVE DISORDER. Analysis of Hollon S, et al., Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, F1000Research 2015, 4:639 (doi: 10.12688/f1000research.6954.1). U.S. National Library of Medicine version.

Articles by Douglas Berger, M.D., Ph.D. for Tokyo Families magazine:

Related Twitter feeds:

Contact Us